DE60144543D1 - Oral verabreichte Peptide zur Linderung von Atherosklerose - Google Patents

Oral verabreichte Peptide zur Linderung von Atherosklerose

Info

Publication number
DE60144543D1
DE60144543D1 DE60144543T DE60144543T DE60144543D1 DE 60144543 D1 DE60144543 D1 DE 60144543D1 DE 60144543 T DE60144543 T DE 60144543T DE 60144543 T DE60144543 T DE 60144543T DE 60144543 D1 DE60144543 D1 DE 60144543D1
Authority
DE
Germany
Prior art keywords
atherosclerosis
relief
peptides
orally administered
administered peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60144543T
Other languages
German (de)
English (en)
Inventor
Alan M Fogelman
Mohammad Navab
Gattadahalli M Anantharamaiah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Application granted granted Critical
Publication of DE60144543D1 publication Critical patent/DE60144543D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
DE60144543T 2000-08-24 2001-08-23 Oral verabreichte Peptide zur Linderung von Atherosklerose Expired - Lifetime DE60144543D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/645,454 US6664230B1 (en) 2000-08-24 2000-08-24 Orally administered peptides to ameliorate atherosclerosis

Publications (1)

Publication Number Publication Date
DE60144543D1 true DE60144543D1 (de) 2011-06-09

Family

ID=24589089

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60141842T Expired - Lifetime DE60141842D1 (de) 2000-08-24 2001-08-23 Erosklerose
DE60144543T Expired - Lifetime DE60144543D1 (de) 2000-08-24 2001-08-23 Oral verabreichte Peptide zur Linderung von Atherosklerose

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE60141842T Expired - Lifetime DE60141842D1 (de) 2000-08-24 2001-08-23 Erosklerose

Country Status (15)

Country Link
US (2) US6664230B1 (enExample)
EP (3) EP1864675B1 (enExample)
JP (6) JP3822167B2 (enExample)
CN (6) CN100579984C (enExample)
AT (2) ATE464060T1 (enExample)
AU (4) AU8673201A (enExample)
CA (3) CA2718348C (enExample)
CY (1) CY1110204T1 (enExample)
DE (2) DE60141842D1 (enExample)
DK (1) DK1318828T3 (enExample)
EA (2) EA009528B1 (enExample)
ES (2) ES2438779T3 (enExample)
IL (3) IL154545A0 (enExample)
PT (1) PT1318828E (enExample)
WO (1) WO2002015923A1 (enExample)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723303B2 (en) 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US7199102B2 (en) * 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7166578B2 (en) * 2000-08-24 2007-01-23 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US7144862B2 (en) * 2000-08-24 2006-12-05 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US6664230B1 (en) * 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US8568766B2 (en) * 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US6930085B2 (en) 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis
DE10222234A1 (de) * 2002-05-16 2003-11-27 Roche Diagnostics Gmbh Kontroll- und Kalibrationsmaterial für Blutgerinnungstests
AU2003287288A1 (en) * 2002-10-30 2004-06-07 The United States Of America As Represented By The Secretary Of Health And Human Services, Nih Scavenger receptor b1 (cla-1) targeting for the treatment of infection, sepsis and inflammation
EP3254673A1 (en) * 2002-11-13 2017-12-13 The UAB Research Foundation Synthetic single domain polypeptides mimicking apolipoprotein e and methods of use
US20050159362A1 (en) * 2003-04-22 2005-07-21 Sircar Jagadish C. Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia
PE20050136A1 (es) * 2003-04-22 2005-04-20 Avanir Pharmaceuticals Mediadores peptidicos del transporte inverso de colesterol para el tratamiento de hipercolesterolemia
GB0311081D0 (en) * 2003-05-14 2003-06-18 Btg Internat Limted Treatment of neurodegenerative conditions
JP2007502805A (ja) * 2003-08-18 2007-02-15 ビーティージー・インターナショナル・リミテッド 神経変性状態の処置
US7781219B2 (en) 2003-12-05 2010-08-24 The Cleveland Clinic Foundation Risk markers for cardiovascular disease
GB0329958D0 (en) 2003-12-24 2004-01-28 Univ Manchester Treatment of viral infections
GB0404374D0 (en) 2004-02-27 2004-03-31 Univ Manchester Treatment of bacterial infections
WO2005100405A2 (en) * 2004-04-15 2005-10-27 Athera Biotechnologies Ab Phosphorylcholine conjugates and corresponding antibodies
US8226977B2 (en) * 2004-06-04 2012-07-24 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
CA2568539A1 (en) * 2004-06-09 2005-12-29 Avanir Pharmaceuticals Small molecules for treatment of hypercholesterolemia and related diseases
WO2005123770A1 (en) * 2004-06-09 2005-12-29 Avanir Pharmaceuticals Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia
AU2005255011A1 (en) * 2004-06-09 2005-12-29 Avanir Pharmaceuticals Heterocyclic derivatives for treatment of hyperlipidemia and related diseases
US7569546B2 (en) 2004-07-16 2009-08-04 Trustees Of Tufts College Apolipoprotein A1 mimetics and uses thereof
US7378396B2 (en) 2004-08-11 2008-05-27 The Cleveland Clinic Foundation Therapeutic agents and methods for cardiovascular disease
US20060173067A1 (en) * 2004-08-11 2006-08-03 The Regents Of The University Of California Small molecules for the treatment of atherosclerosis
US20060205669A1 (en) * 2004-09-16 2006-09-14 The Regents Of The University Of California G-type peptides and other agents to ameliorate atherosclerosis and other pathologies
WO2006053754A1 (en) * 2004-11-19 2006-05-26 Novartis Ag COMBINATIONS OF ANTI-ATHEROSCLEROTIC PEPTIDES AND AN mTOR INHIBITING AGENT AND THEIR METHODS OF USE
GB0425932D0 (en) * 2004-11-25 2004-12-29 Btg Int Ltd Structured phospholipids
CN101115496B (zh) * 2004-12-06 2012-03-07 加州大学评议会 改善微动脉的结构和功能的方法
GB0504362D0 (en) * 2005-03-02 2005-04-06 Btg Int Ltd Cytokine modulators
GB0504333D0 (en) * 2005-03-02 2005-04-06 Btg Int Ltd Treatment of cytokine dysregulation
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
NZ563187A (en) * 2005-04-29 2010-05-28 Univ California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US20080293639A1 (en) * 2005-04-29 2008-11-27 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
GR1005428B (el) * 2005-05-27 2007-02-01 Χαραλαμπος Αλεξοπουλος Συνθετικα λιποπεπτιδια με αντιαθηρογονο δραση, που εμποδιζουν την οξειδωση της λιποπρωτεϊνης χαμηλης πυκνοτητας (ldl) και αναστελλουν την απενεργοποιηση του ενζυμου της paf ακετυλοϋδρολασης (paf-ah)
GB0513096D0 (en) 2005-06-28 2005-08-03 Strathclyde Treatment of microbial infections
WO2007055873A2 (en) * 2005-11-04 2007-05-18 Avanir Pharmaceuticals Process for the manufacture of peptide facilitators of reverse cholesterol transport
US8440695B2 (en) * 2005-11-09 2013-05-14 St Jude Children's Research Hospital Use of chloroquine to treat metabolic syndrome
ES2402823T3 (es) * 2006-06-01 2013-05-09 Institut De Cardiologie De Montreal Compuesto para uso en el tratamiento de estenosis valvular
US20080227686A1 (en) * 2006-06-16 2008-09-18 Lipid Sciences, Inc. Novel Peptides that Promote Lipid Efflux
US20080199398A1 (en) * 2006-06-16 2008-08-21 Brewer H Bryan Novel Peptides That Promote Lipid Efflux
US20080206142A1 (en) * 2006-06-16 2008-08-28 Lipid Sciences, Inc. Novel Peptides That Promote Lipid Efflux
AU2007284801A1 (en) * 2006-08-08 2008-02-21 The Regents Of The University Of Californina Salicylanilides enhance oral delivery of therapeutic peptides
US20080138284A1 (en) * 2006-09-26 2008-06-12 Lipid Sciences, Inc. Novel Peptides That Promote Lipid Efflux
EP2121746B1 (en) * 2006-12-13 2011-11-16 The Regents of the University of California Potent and selective mediators of cholesterol efflux
US20080268038A1 (en) * 2007-04-26 2008-10-30 Wolfe Robert R Compositions and Approaches for Increasing Diet Induced Thermogenesis, Inducing Weight Loss and Maintaining Muscle Mass and Strength
RU2010104042A (ru) * 2007-07-09 2011-08-20 Новартис АГ (CH) Сохранение вторичной структуры пептида
WO2009032693A2 (en) 2007-08-28 2009-03-12 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
CA2697957A1 (en) * 2007-08-28 2009-03-12 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
HRP20150330T1 (hr) * 2007-08-30 2015-06-19 Curedm Group Holdings, Llc Pripravci i postupci uporabe prostaniäśnog peptida za stanice otoäśiä†a i njegovih analoga
CA2709151A1 (en) * 2007-12-11 2009-06-18 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments
US20110020242A1 (en) * 2007-12-12 2011-01-27 Gang Zheng High-density lipoprotein-like peptide-phospholipid scaffold ("hpps") nanoparticles
US20100093624A1 (en) * 2008-07-30 2010-04-15 Cosmix Therapeutics Llc Peptide therapeutics that bind vegf and methods of use thereof
ITTO20080894A1 (it) * 2008-12-02 2010-06-03 Bioindustry Park Del Canavese S P A Uso dell'aptoglobina, peptidi leganti l'aptoglobina, polimeri contenenti gli stessi e loro uso
SMT201700203T1 (it) 2009-02-16 2017-05-08 Cerenis Therapeutics Holding Sa Mimetici di apolipoproteina a-i
EP2484692A4 (en) * 2009-09-30 2013-03-06 Snu R&Db Foundation MIMETIC APOLIPOPROTEIN A-1-PEPTIDES AND THERAPEUTICS FOR THE TREATMENT OF HYPERLIPIDEMIA AND DISEASES RELATED TO HYPERLIPIDEMIA THEREWITH
US10525152B2 (en) 2009-10-09 2020-01-07 Signablok, Inc. Methods and compositions for targeted imaging
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
US12419839B2 (en) 2009-10-09 2025-09-23 Signablok, Inc. Methods and compositions for targeted delivery of protein fragments
DK2385374T4 (en) 2010-05-05 2018-04-30 Zora Biosciences Oy LIPIDOMICS BIOMARKERS FOR ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASE
CN103154742B (zh) * 2010-06-20 2017-11-21 佐拉生物科学公司 用于鉴定高风险冠状动脉疾病患者的脂质组学标志
HUE042314T2 (hu) 2011-02-07 2019-06-28 Cerenis Therapeutics Holding Sa Lipoprotein komplexek és azok gyártása és alkalmazásai
WO2012108990A2 (en) * 2011-02-07 2012-08-16 Indiana University Research And Technology Corporation Peptide-phospholipid conjugates
US9539300B2 (en) 2012-03-31 2017-01-10 The Regents Of The University Of California Modulating disease through genetic engineering of plants
BR112015010276A2 (pt) * 2012-11-06 2019-10-15 Hoffmann La Roche peptídeos miméticos
US20160002315A1 (en) 2013-03-14 2016-01-07 Uab Research Foundation Apolipoprotein mimetics and uses thereof
EP2983687B1 (en) 2013-03-15 2019-09-04 The Regents of The University of California Peptides having reduced toxicity that stimulate cholesterol efflux
EP2989120A4 (en) 2013-04-25 2017-04-19 Carmel-Haifa University Economic Corp. Synthetic anti-inflammatory peptides and use thereof
EP2853259A1 (en) 2013-09-30 2015-04-01 Université Pierre et Marie Curie (Paris 6) Reconstituted high density lipoproteins composition and uses thereof
BR112016025470A2 (pt) 2014-05-02 2017-08-15 Cerenis Therapeutics Holding S A ?hdl terapêutico?
WO2016018665A1 (en) 2014-07-31 2016-02-04 Uab Research Foundation Apoe mimetic peptides and higher potency to clear plasma cholesterol
JP2018528257A (ja) 2015-07-10 2018-09-27 ペプティノボ・バイオファーマ・リミテッド・ライアビリティ・カンパニーＰｅｐｔｉｎｏｖｏ Ｂｉｏｐｈａｒｍａ， ＬＬＣ 疎水性薬剤の効能を改善するための配合物
CN105061579B (zh) * 2015-08-18 2018-08-28 北京大学人民医院 脂多糖结合蛋白在制备类风湿关节炎相关药物中的应用
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
BR112019001459A2 (pt) 2016-07-27 2019-05-07 Hartis-Pharma Sa combinação, composição farmacêutica, e, método de prevenção e/ou de tratamento de uma doença ou de um distúrbio.
US10905736B2 (en) 2016-09-28 2021-02-02 The Regents Of The University Of California Ezetimibe-associated ApoA-I mimetic peptides showing enhanced synergism
US10426817B2 (en) 2017-01-24 2019-10-01 Macregen, Inc. Treatment of age-related macular degeneration and other eye diseases with apolipoprotein mimetics
IT201800009384A1 (it) * 2018-10-11 2020-04-11 Cosmo Srl Peptide for cosmetic application
CN115427064A (zh) 2020-04-16 2022-12-02 阿比奥尼克斯制药公司 使用基于脂质结合蛋白的复合物治疗急性病况的方法
EP4221686A2 (en) 2020-10-01 2023-08-09 Abionyx Pharma SA Compositions comprising lipid binding protein-based complexes for use for treating eye diseases
RU2760498C1 (ru) * 2021-02-09 2021-11-25 Вахтанг Владимирович Гобеджишвили Способ прогнозирования развития избыточного рубцеобразования у больных после проктологической операции
JP2024514154A (ja) 2021-04-15 2024-03-28 アビオニクス ファーマ エスエー 臓器保存溶液における脂質結合タンパク質ベースの複合体の使用
US20250066452A1 (en) * 2022-03-03 2025-02-27 University Of Maryland, Baltimore Synthetic amphipathic helical peptides and treatment methods using synthetic amphipathic helical peptides
AU2023250345A1 (en) 2022-04-06 2024-11-14 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
CA3247588A1 (en) 2022-04-06 2023-10-12 Abionyx Pharma Sa METHODS FOR TREATING LEUKOCYTOSIS, ENDOTHELIAL DYSFUNCTION AND CARDITIS USING LIPID-BINDING PROTEIN COMPLEXES
AU2023284357A1 (en) 2022-06-10 2025-01-23 Abionyx Pharma Sa Methods for treating acute conditions using lipid binding protein-based complexes
WO2023237927A2 (en) 2022-06-10 2023-12-14 Abionyx Pharma Sa Methods for treating hyperinflammatory conditions using lipid binding protein -based complexes
IL322074A (en) 2023-01-13 2025-09-01 Abionyx Pharma Sa Treatment using a lipid-binding protein molecule
WO2025093929A1 (en) 2023-10-31 2025-05-08 Abionyx Pharma Sa Lipid binding protein molecule therapy
WO2025147594A1 (en) * 2024-01-04 2025-07-10 University Of Florida Research Foundation, Incorporated Peptides and method of use in preparing nanodiscs

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3767040A (en) 1971-03-01 1973-10-23 Minnesota Mining & Mfg Pressure-sensitive polyurethane adhesives
US4155913A (en) 1973-02-08 1979-05-22 Hoffmann-La Roche Inc. Thienotriazolodiazepine derivatives
NO812612L (no) 1980-08-06 1982-02-08 Ferring Pharma Ltd Enzym-inhibitorer.
US4643988A (en) 1984-05-15 1987-02-17 Research Corporation Amphipathic peptides
US5182261A (en) * 1989-07-13 1993-01-26 The Rockefeller University Modified transforming growth factor alpha oligopeptides and pharmaceutical compositions thereof
AU662885B2 (en) 1990-06-07 1995-09-21 Scripps Research Institute, The APO AI polypeptides, antibodies, and immunoassays
GB9022788D0 (en) 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
US5646119A (en) * 1991-11-01 1997-07-08 Periodontix, Inc. D-amino acid histatin-based peptides as anti-fungal and anti-bacterial agents
SE9103701D0 (sv) * 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein
WO1993025581A1 (en) 1992-06-12 1993-12-23 N.V. Innogenetics S.A. New peptides and proteins, process for their preparation and their use as cholesterol acceptors
US5344822A (en) 1992-08-12 1994-09-06 The Rogosin Institute Methods useful in endotoxin prophylaxis and therapy
WO1994004563A1 (fr) 1992-08-14 1994-03-03 Shino-Test Corporation PEPTIDES CONTENANT DES SEQUENCES D'ACIDES AMINES RESPECTIVES SELECTIONNEES PARMI CELLES DE LA LIPOPROTEINE(a) ET DE L'APOLIPOPROTEINE(a), ANTICORPS RECONNAISSANT CES SEQUENCES D'ACIDES AMINES ET PROCEDE D'ANALYSE UTILISANT CES ANTICORPS
US5721138A (en) 1992-12-15 1998-02-24 Sandford University Apolipoprotein(A) promoter and regulatory sequence constructs and methods of use
DK0735893T3 (da) * 1993-09-14 2009-03-09 Pharmexa Inc PAN DR-bindende peptider til styrkelse af immunsvaret
US6169073B1 (en) * 1995-02-16 2001-01-02 Bayer Corporation Peptides and peptidomimetics with structural similarity to human p53 that activate p53 function
KR19990044460A (ko) 1995-09-09 1999-06-25 프리돌린 클라우스너, 롤란드 비. 보레르 아포리포단백질 에이-아이의 양을 증대시키는 티에노트리아졸로디아제핀의 용도
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
WO1997036927A1 (en) 1996-03-29 1997-10-09 Dario Boffelli Amphipathic molecules as cholesterol and other lipid uptake inhibitors
US6200955B1 (en) * 1996-06-11 2001-03-13 Commonwealth Biotechnologies, Inc. Heparin binding peptides
US6156727A (en) * 1996-09-05 2000-12-05 Uab Research Foundation Anti-atherosclerotic peptides and a transgenic mouse model of antherosclerosis
US6696545B1 (en) * 1997-04-11 2004-02-24 Sangstat Medical Corporation Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation
IN185761B (enExample) 1997-05-13 2001-04-28 Council Scient Ind Res
US6046166A (en) 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6037323A (en) 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6518412B1 (en) 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6287590B1 (en) 1997-10-02 2001-09-11 Esperion Therapeutics, Inc. Peptide/lipid complex formation by co-lyophilization
AU3356899A (en) 1998-03-17 1999-10-11 Uab Research Foundation, The Synthetic peptides that enhance ldl uptake
JP5101764B2 (ja) * 1998-07-30 2012-12-19 ホワイトヘッド インスチチュート フォアー バイオメディカル リサーチ Ｈｉｖ膜融合のインヒビター
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis

Also Published As

Publication number Publication date
CA2718348A1 (en) 2002-02-28
AU2006200035B2 (en) 2007-09-13
ES2438779T3 (es) 2014-01-20
US20030045460A1 (en) 2003-03-06
JP2008150358A (ja) 2008-07-03
CN100579984C (zh) 2010-01-13
EP2198877A3 (en) 2010-12-01
WO2002015923A1 (en) 2002-02-28
EP1318828A1 (en) 2003-06-18
JP4205713B2 (ja) 2009-01-07
JP2007277250A (ja) 2007-10-25
EP1318828A4 (en) 2005-04-27
EA009528B1 (ru) 2008-02-28
CA2639651C (en) 2011-02-08
AU2009202705A1 (en) 2009-07-23
AU2009202705B2 (en) 2013-01-10
CN1931359A (zh) 2007-03-21
CN1739787A (zh) 2006-03-01
HK1055400A1 (en) 2004-01-09
JP4364222B2 (ja) 2009-11-11
IL206114A (en) 2014-05-28
CA2420222C (en) 2009-03-03
JP2004506693A (ja) 2004-03-04
JP2006056899A (ja) 2006-03-02
CN1931358A (zh) 2007-03-21
EP1864675B1 (en) 2011-04-27
CA2718348C (en) 2012-07-17
IL154545A0 (en) 2003-09-17
AU2006200035A1 (en) 2006-02-02
AU2001286732B2 (en) 2005-10-06
CN1931359B (zh) 2014-10-15
DK1318828T3 (da) 2010-08-09
CN1224419C (zh) 2005-10-26
CY1110204T1 (el) 2015-01-14
ATE506958T1 (de) 2011-05-15
JP2006312650A (ja) 2006-11-16
EP1318828B1 (en) 2010-04-14
ES2342258T3 (es) 2010-07-05
PT1318828E (pt) 2010-06-11
DE60141842D1 (de) 2010-05-27
JP2010280718A (ja) 2010-12-16
CA2420222A1 (en) 2002-02-28
EA006488B1 (ru) 2005-12-29
US6933279B2 (en) 2005-08-23
JP5241790B2 (ja) 2013-07-17
AU8673201A (en) 2002-03-04
CN1911439A (zh) 2007-02-14
EA200300289A1 (ru) 2003-08-28
JP3822167B2 (ja) 2006-09-13
IL154545A (en) 2011-10-31
CN1469754A (zh) 2004-01-21
EP1864675A1 (en) 2007-12-12
EP2198877A2 (en) 2010-06-23
US6664230B1 (en) 2003-12-16
CN1943781B (zh) 2011-01-12
AU2009202705C1 (en) 2013-10-17
ATE464060T1 (de) 2010-04-15
HK1110011A1 (en) 2008-07-04
CN1943781A (zh) 2007-04-11
EP2198877B1 (en) 2013-10-16
EA200501744A1 (ru) 2006-06-30
CA2639651A1 (en) 2002-02-28

Similar Documents

Publication Publication Date Title
DE60144543D1 (de) Oral verabreichte Peptide zur Linderung von Atherosklerose
ATE516811T1 (de) Peptide vom g-typ zur linderung von atherosklerose
DK1180524T4 (da) Neuronal exocytose-hæmmende peptider og kosmetiske og farmaceutiske sammensætninger indeholdende de nævnte peptider
ATE260644T1 (de) Peptid/lipid-komplexbildung durch co- lyophilisation
DE69928270D1 (de) Neutraler aminosäurentransporter und korrespondierendes gen
ATE169304T1 (de) Biologisch aktive peptide aus funktionellen domaenen des bakteriziden/ die permeabilitaet erhoehenden proteins und ihre verwendung
HUP9801562A3 (en) Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
BR0205983A (pt) fármacos peptìdicos antiangiogênicos
HUP9800518A3 (en) Heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
NO20073914L (no) Biologisk aktive peptider
BR9714376A (pt) Antagonistas de somatostatina
DK1219299T4 (da) Allergivacciner og fremstilling deraf
BG103859A (en) The use of 1-ar(alk)yl-imidazolin-2-on for the treatment of fear and stress conditions
AU4225001A (en) Novel polypeptide---human excitatory amino acid transporter protein 10 and polynucleotide encoding it
AU4224601A (en) Novel polypeptide---human excitatory amino acid transporter protein 9 and polynucleotide encoding it
BR0107799A (pt) Proteìna de interação de wt1 wtip
SI0813542T1 (en) Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors